{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:14:05Z","timestamp":1761513245586,"version":"build-2065373602"},"reference-count":80,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,2,11]],"date-time":"2013-02-11T00:00:00Z","timestamp":1360540800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["accpjournals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pharmacotherapy"],"published-print":{"date-parts":[[2013,3]]},"abstract":"<jats:p>\n                    Seizures are a frequent complication associated with several neurogenetic disorders. Antiepileptic medications remain the mainstay of treatment in these patients. We summarized the available data associated with various antiepileptic therapies used to treat patients with neurogenetic disorders who experienced recurrent seizures. A\n                    <jats:styled-content style=\"fixed-case\">MEDLINE<\/jats:styled-content>\n                    search was conducted to identify articles and abstracts describing the use of antiepileptic therapy for the treatment of various neurogenetic syndromes. Of all the neurogenetic syndromes, only autism spectrum disorders, Angelman syndrome,\n                    <jats:styled-content style=\"fixed-case\">R<\/jats:styled-content>\n                    ett syndrome,\n                    <jats:styled-content style=\"fixed-case\">D<\/jats:styled-content>\n                    ravet syndrome, and tuberous sclerosis complex were identified as having sufficient published information to evaluate therapy. Some efficacy trends were identified, including frequent successes with valproic acid with clonazepam for epilepsy with Angelman syndrome; valproic acid, stiripentol, and clobazam (triple combination therapy) for epilepsy with Dravet syndrome; and vigabatrin for infantile spasms associated with tuberous sclerosis complex. Due to a paucity of information regarding the mechanisms by which seizures are generated in the various disorders, approach to seizure control is primarily based on clinical experience and a limited amount of study data exploring patient outcomes. Although exposure of the developing brain to antiepileptic medications is of some concern, the control of epileptic activity is an important undertaking in these individuals, as the severity of eventual developmental delay often appears to correlate with the severity of seizures. As such, early aggressive therapy is warranted.\n                  <\/jats:p>","DOI":"10.1002\/phar.1201","type":"journal-article","created":{"date-parts":[[2013,2,11]],"date-time":"2013-02-11T11:27:07Z","timestamp":1360582027000},"page":"330-343","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Neurogenetic Disorders and Treatment of Associated Seizures"],"prefix":"10.1002","volume":"33","author":[{"given":"Michele A.","family":"Faulkner","sequence":"first","affiliation":[{"name":"Departments of Pharmacy Practice and Neurology Creighton University School of Pharmacy and Health Professions Omaha Nebraska"},{"name":"Creighton University School of Pharmacy and Health Professions Omaha Nebraska"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sanjay P.","family":"Singh","sequence":"additional","affiliation":[{"name":"Creighton University School of Pharmacy and Health Professions Omaha Nebraska"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,2,11]]},"reference":[{"key":"e_1_2_4_2_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-007-0012-7"},{"key":"e_1_2_4_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddrr.116"},{"key":"e_1_2_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11065-007-9048-4"},{"key":"e_1_2_4_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2011.03394.x"},{"key":"e_1_2_4_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11910-011-0195-x"},{"key":"e_1_2_4_7_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181f6bc97"},{"key":"e_1_2_4_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(02)00160-6"},{"key":"e_1_2_4_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2005.57504.x"},{"key":"e_1_2_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2010.07.002"},{"key":"e_1_2_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10803-009-0883-4"},{"key":"e_1_2_4_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/mrdd.20026"},{"key":"e_1_2_4_13_1","doi-asserted-by":"publisher","DOI":"10.1002\/0470869380.ch8"},{"key":"e_1_2_4_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.brainresbull.2003.06.001"},{"key":"e_1_2_4_15_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2431-11-37"},{"key":"e_1_2_4_16_1","doi-asserted-by":"publisher","DOI":"10.2165\/00148581-200305100-00001"},{"key":"e_1_2_4_17_1","doi-asserted-by":"publisher","DOI":"10.1097\/GIM.0b013e3181def138"},{"key":"e_1_2_4_18_1","doi-asserted-by":"publisher","DOI":"10.1038\/ejhg.2009.67"},{"key":"e_1_2_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2003.09.015"},{"key":"e_1_2_4_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2009.02108.x"},{"key":"e_1_2_4_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb01097.x"},{"key":"e_1_2_4_22_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320280107"},{"key":"e_1_2_4_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320320235"},{"key":"e_1_2_4_24_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajmg.1320280407"},{"key":"e_1_2_4_25_1","doi-asserted-by":"crossref","first-page":"2583","DOI":"10.1093\/ajhp\/60.24.2583","article-title":"Assessment of anticonvulsant effectiveness and safety in patients with Angelman's syndrome using an Internet questionnaire","volume":"60","author":"Nolt DH","year":"2003","journal-title":"Am J Health Syst Pharm"},{"key":"e_1_2_4_26_1","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1684\/j.1950-6945.2005.tb00095.x","article-title":"Analysis of the characteristics of epilepsy in 37 patients with the molecular diagnosis of Angelman syndrome","volume":"7","author":"Galv\u00e1n\u2010Manso M","year":"2005","journal-title":"Epileptic Disord"},{"key":"e_1_2_4_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.63.1.122"},{"key":"e_1_2_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2006.00969.x"},{"key":"e_1_2_4_29_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.54.5.1185"},{"key":"e_1_2_4_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01314.x"},{"key":"e_1_2_4_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2009.10.005"},{"key":"e_1_2_4_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2006.09.003"},{"key":"e_1_2_4_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2006.10.003"},{"key":"e_1_2_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738050200082101"},{"key":"e_1_2_4_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0883073811408422"},{"key":"e_1_2_4_36_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181d6b852"},{"key":"e_1_2_4_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1651-2227.2001.tb00252.x"},{"key":"e_1_2_4_38_1","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M101287200"},{"key":"e_1_2_4_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0896-6273(02)00768-7"},{"key":"e_1_2_4_40_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2007.01423.x"},{"key":"e_1_2_4_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1990.tb05494.x"},{"key":"e_1_2_4_42_1","first-page":"57","article-title":"Stiripentol: severe myoclonic epilepsy of infancy: promising","volume":"14","author":"Prescrire Editorial Team","year":"2005","journal-title":"Prescrire Int"},{"key":"e_1_2_4_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01922.x"},{"key":"e_1_2_4_44_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.braindev.2008.03.002"},{"key":"e_1_2_4_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03157-3"},{"key":"e_1_2_4_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eplepsyres.2011.03.005"},{"key":"e_1_2_4_47_1","doi-asserted-by":"publisher","DOI":"10.1113\/jphysiol.2010.187484"},{"key":"e_1_2_4_48_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307389701200407"},{"key":"e_1_2_4_49_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1998.tb01413.x"},{"key":"e_1_2_4_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(03)00028-7"},{"key":"e_1_2_4_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(02)00010-4"},{"key":"e_1_2_4_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2005.01.006"},{"key":"e_1_2_4_53_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000265222.24102.db"},{"key":"e_1_2_4_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.seizure.2005.12.004"},{"key":"e_1_2_4_55_1","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-200868140-00001"},{"key":"e_1_2_4_56_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1999.tb02048.x"},{"key":"e_1_2_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(97)00099-5"},{"key":"e_1_2_4_58_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737175.8.3.457"},{"key":"e_1_2_4_59_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738050200040901"},{"key":"e_1_2_4_60_1","doi-asserted-by":"publisher","DOI":"10.1177\/08830738040190090801"},{"key":"e_1_2_4_61_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1750-3639.2002.tb00437.x"},{"key":"e_1_2_4_62_1","doi-asserted-by":"publisher","DOI":"10.1523\/JNEUROSCI.2687-05.2005"},{"key":"e_1_2_4_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clineuro.2008.08.004"},{"key":"e_1_2_4_64_1","unstructured":"National Institute for Clinical Excellence(2004).The diagnosis and management of the epilepsies in adults and children in primary and secondary care. Clinical Guideline 20.London:National Institute for Health and Clinical Excellence. Available fromhttp:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG020fullguideline.pdf. Accessed February 27 2012."},{"key":"e_1_2_4_65_1","unstructured":"Scottish Intercollegiate Guidelines Network(2005).Diagnosis and management of epilepsies in children and young people. A national clinical guideline #81. SIGN. Available fromhttp:\/\/www.sign.ac.uk\/pdf\/sign81.pdf. Accessed February 24 2012."},{"key":"e_1_2_4_66_1","doi-asserted-by":"publisher","DOI":"10.1177\/088307380502000101"},{"key":"e_1_2_4_67_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.1997.tb00063.x"},{"key":"e_1_2_4_68_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01988.x"},{"key":"e_1_2_4_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0920-1211(99)00082-0"},{"key":"e_1_2_4_70_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2009.03.004"},{"key":"e_1_2_4_71_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nurt.2006.11.008"},{"key":"e_1_2_4_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1167.2008.01961.x"},{"key":"e_1_2_4_73_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1091-8531(00)70009-7"},{"key":"e_1_2_4_74_1","doi-asserted-by":"publisher","DOI":"10.1167\/iovs.04-0559"},{"key":"e_1_2_4_75_1","first-page":"87","article-title":"Topiramate as therapy for tuberous sclerosis complex\u2010associated seizures","volume":"41","author":"Franz DN","year":"2000","journal-title":"Epilepsia"},{"key":"e_1_2_4_76_1","first-page":"680","article-title":"Topiramate as adjunctive therapy for partial seizures in patients with tuberous sclerosis complex","volume":"16","author":"Bartalini G","year":"2001","journal-title":"J Child Neurol"},{"key":"e_1_2_4_77_1","first-page":"680","article-title":"Oxcarbazepine therapy of epilepsy in tuberous sclerosis complex","volume":"16","author":"Franz DN","year":"2001","journal-title":"J Child Neurol"},{"key":"e_1_2_4_78_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1528-1157.2001.042007935.x"},{"key":"e_1_2_4_79_1","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.60.9.1286"},{"key":"e_1_2_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpn.2011.03.010"},{"key":"e_1_2_4_81_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.WNL.0000115653.82763.07"}],"container-title":["Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fphar.1201","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/phar.1201","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:14:40Z","timestamp":1761070480000},"score":1,"resource":{"primary":{"URL":"https:\/\/accpjournals.onlinelibrary.wiley.com\/doi\/10.1002\/phar.1201"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,2,11]]},"references-count":80,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2013,3]]}},"alternative-id":["10.1002\/phar.1201"],"URL":"https:\/\/doi.org\/10.1002\/phar.1201","archive":["Portico"],"relation":{},"ISSN":["0277-0008","1875-9114"],"issn-type":[{"type":"print","value":"0277-0008"},{"type":"electronic","value":"1875-9114"}],"subject":[],"published":{"date-parts":[[2013,2,11]]},"assertion":[{"value":"2013-02-11","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}